Helus Pharma Appoints Dr. Ken Kramer as SVP, Medical Affairs, Strengthening Neuroscience Leadership

summarizeSummary

Helus Pharma, operating as Cybin Inc., has appointed Dr. Ken Kramer as Senior Vice President of Medical Affairs, bringing 25 years of neuroscience and neuropsychiatry launch experience to support its clinical pipeline.

check_boxKey Events

• Key Executive Appointment

  Dr. Ken Kramer, PhD, has been appointed Senior Vice President, Medical Affairs, effective immediately.

• Strengthens Medical Leadership

  Dr. Kramer brings 25 years of experience in neuroscience and neuropsychiatry, including leadership roles at Bristol Myers Squibb, Karuna Therapeutics, and AbbVie, where he led successful product launches.

• Supports Clinical Pipeline Advancement

  His expertise is critical for advancing Helus Pharma's Phase 3 (HLP003) and Phase 2 (HLP004) programs and preparing for potential commercialization of its novel serotonergic agonists.

auto_awesomeAnalysis

This appointment is a significant positive development for Helus Pharma (operating as Cybin Inc.), a clinical-stage company with Phase 3 and Phase 2 assets. Dr. Kramer's extensive experience in medical affairs leadership at major pharmaceutical companies like Bristol Myers Squibb and AbbVie, particularly in neuroscience and neuropsychiatry, is directly relevant to Helus's focus on novel serotonergic agonists for mental health conditions. His expertise in global launch readiness and engagement with key opinion leaders will be instrumental as the company advances its pipeline, including HLP003 with Breakthrough Therapy Designation, towards potential commercialization. This hire strengthens the company's scientific and clinical engagement capabilities, which is crucial for a biotech moving through late-stage development.